|
Gene: NKIRAS2 |
Gene summary for NKIRAS2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NKIRAS2 | Gene ID | 28511 |
Gene name | NFKB inhibitor interacting Ras like 2 | |
Gene Alias | KBRAS2 | |
Cytomap | 17q21.2 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A024R1Z4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28511 | NKIRAS2 | P52T-E | Human | Esophagus | ESCC | 1.89e-22 | 5.35e-01 | 0.1555 |
28511 | NKIRAS2 | P54T-E | Human | Esophagus | ESCC | 3.14e-12 | 3.40e-01 | 0.0975 |
28511 | NKIRAS2 | P56T-E | Human | Esophagus | ESCC | 3.54e-10 | 1.17e+00 | 0.1613 |
28511 | NKIRAS2 | P57T-E | Human | Esophagus | ESCC | 1.73e-12 | 2.56e-01 | 0.0926 |
28511 | NKIRAS2 | P61T-E | Human | Esophagus | ESCC | 2.37e-20 | 6.15e-01 | 0.099 |
28511 | NKIRAS2 | P62T-E | Human | Esophagus | ESCC | 3.06e-53 | 8.25e-01 | 0.1302 |
28511 | NKIRAS2 | P65T-E | Human | Esophagus | ESCC | 1.40e-16 | 2.85e-01 | 0.0978 |
28511 | NKIRAS2 | P74T-E | Human | Esophagus | ESCC | 6.49e-26 | 7.29e-01 | 0.1479 |
28511 | NKIRAS2 | P75T-E | Human | Esophagus | ESCC | 4.69e-40 | 8.00e-01 | 0.1125 |
28511 | NKIRAS2 | P76T-E | Human | Esophagus | ESCC | 1.60e-31 | 6.80e-01 | 0.1207 |
28511 | NKIRAS2 | P79T-E | Human | Esophagus | ESCC | 3.14e-41 | 8.36e-01 | 0.1154 |
28511 | NKIRAS2 | P80T-E | Human | Esophagus | ESCC | 7.80e-40 | 1.17e+00 | 0.155 |
28511 | NKIRAS2 | P82T-E | Human | Esophagus | ESCC | 1.46e-10 | 6.87e-01 | 0.1072 |
28511 | NKIRAS2 | P83T-E | Human | Esophagus | ESCC | 4.38e-43 | 1.11e+00 | 0.1738 |
28511 | NKIRAS2 | P84T-E | Human | Esophagus | ESCC | 5.62e-10 | 5.49e-01 | 0.0933 |
28511 | NKIRAS2 | P89T-E | Human | Esophagus | ESCC | 2.00e-19 | 1.11e+00 | 0.1752 |
28511 | NKIRAS2 | P91T-E | Human | Esophagus | ESCC | 1.03e-16 | 1.27e+00 | 0.1828 |
28511 | NKIRAS2 | P107T-E | Human | Esophagus | ESCC | 7.62e-56 | 1.10e+00 | 0.171 |
28511 | NKIRAS2 | P126T-E | Human | Esophagus | ESCC | 1.31e-04 | 6.11e-01 | 0.1125 |
28511 | NKIRAS2 | P127T-E | Human | Esophagus | ESCC | 1.90e-15 | 2.52e-01 | 0.0826 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:00072494 | Liver | Cirrhotic | I-kappaB kinase/NF-kappaB signaling | 108/4634 | 281/18723 | 2.21e-07 | 5.64e-06 | 108 |
GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
GO:000724925 | Skin | cSCC | I-kappaB kinase/NF-kappaB signaling | 116/4864 | 281/18723 | 1.33e-08 | 4.08e-07 | 116 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NKIRAS2 | SNV | Missense_Mutation | c.41N>T | p.Ser14Phe | p.S14F | Q9NYR9 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
NKIRAS2 | SNV | Missense_Mutation | c.56C>T | p.Ser19Leu | p.S19L | Q9NYR9 | protein_coding | deleterious(0) | benign(0.201) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
NKIRAS2 | SNV | Missense_Mutation | c.218G>A | p.Arg73Gln | p.R73Q | Q9NYR9 | protein_coding | deleterious(0.04) | benign(0.18) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
NKIRAS2 | SNV | Missense_Mutation | c.152N>A | p.Arg51Gln | p.R51Q | Q9NYR9 | protein_coding | tolerated(0.07) | possibly_damaging(0.746) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
NKIRAS2 | SNV | Missense_Mutation | novel | c.58N>G | p.Ile20Val | p.I20V | Q9NYR9 | protein_coding | tolerated(0.36) | benign(0.042) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NKIRAS2 | SNV | Missense_Mutation | novel | c.94N>A | p.Gly32Ser | p.G32S | Q9NYR9 | protein_coding | tolerated(0.19) | possibly_damaging(0.474) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NKIRAS2 | SNV | Missense_Mutation | c.177N>A | p.Phe59Leu | p.F59L | Q9NYR9 | protein_coding | tolerated(0.66) | benign(0.013) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NKIRAS2 | SNV | Missense_Mutation | c.426G>T | p.Glu142Asp | p.E142D | Q9NYR9 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
NKIRAS2 | SNV | Missense_Mutation | rs147962346 | c.385C>T | p.Arg129Cys | p.R129C | Q9NYR9 | protein_coding | deleterious(0.01) | benign(0.046) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
NKIRAS2 | insertion | Frame_Shift_Ins | rs781916716 | c.151_152insG | p.Val53GlyfsTer9 | p.V53Gfs*9 | Q9NYR9 | protein_coding | TCGA-B5-A11G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |